News
The average Wall Street analyst following Editas Medicine (NASDAQ: EDIT) thinks the gene therapy stock can reach $3.25 per share in the next year. From recent prices, this implies a gain of ...
2d
InvestorsHub on MSNDow, S&P 500, and Nasdaq, Wall Street Futures Mixed as Investors Weigh Google and Tesla Earnings Amid Trade Deal OptimismU.S. stock futures moved in different directions on Thursday, with enthusiasm for a potential U.S.-EU trade agreement ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results